Chardan Capital reissued their neutral rating on shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in a report issued on Wednesday morning.

Several other equities analysts have also weighed in on ARWR. ValuEngine lowered shares of Arrowhead Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, June 2nd. Piper Jaffray Companies reiterated a hold rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Friday, July 28th. Jefferies Group LLC reiterated a hold rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Friday, August 4th. Finally, Cantor Fitzgerald reiterated a hold rating and set a $2.00 price objective (up previously from $1.00) on shares of Arrowhead Pharmaceuticals in a report on Friday. One equities research analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. The company has a consensus rating of Hold and a consensus price target of $2.00.

Shares of Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at 3.30 on Wednesday. The firm has a 50 day moving average price of $2.41 and a 200 day moving average price of $1.88. Arrowhead Pharmaceuticals has a 1-year low of $1.20 and a 1-year high of $8.09. The firm’s market cap is $246.75 million.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. The firm had revenue of $9.34 million for the quarter, compared to analyst estimates of $5.29 million. Analysts anticipate that Arrowhead Pharmaceuticals will post ($0.42) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/09/16/arrowhead-pharmaceuticals-arwr-neutral-rating-reaffirmed-at-chardan-capital.html.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 3.4% in the 1st quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock worth $1,226,000 after acquiring an additional 21,654 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Arrowhead Pharmaceuticals by 3.7% in the 1st quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock worth $581,000 after acquiring an additional 11,099 shares during the last quarter. LMR Partners LLP acquired a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth about $467,000. Wells Fargo & Company MN raised its holdings in shares of Arrowhead Pharmaceuticals by 144.8% in the 1st quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock worth $278,000 after acquiring an additional 88,933 shares during the last quarter. Finally, Teachers Advisors LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 18.0% in the 4th quarter. Teachers Advisors LLC now owns 112,642 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 17,201 shares during the last quarter. Institutional investors own 20.63% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.